Plain-English translation of NCT07090499 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called , which is a type of drug designed to attach directly to cancer cells and kill them. The medication is given through an IV infusion (a needle in your vein). Researchers want to find out how safe this treatment is and how well it works in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas.
Advanced cancers in these areas often stop responding to standard treatments, and patients need new options. This medication represents a different approach to fighting cancer, so researchers are testing whether it can be a helpful new tool.
You likely qualify if…
You likely don't qualify if…
The study has multiple phases. In the first part, different groups of participants receive different doses of the medication to find a safe level. In later parts, participants receive the dose that was found to be safest, either in different schedules or as part of groups organized by cancer type. All participants receive the medication through an IV infusion, and you will be closely monitored with blood tests and scans to track how your body responds.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States